Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: Results from the Japanese studies

Tsutomu Takeuchi, Kazuhiko Yamamoto, Hisashi Yamanaka, Naoki Ishiguro, Yoshiya Tanaka, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Toshiharu Shoji, Nobuyuki Miyasaka, Takao Koike

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives. A post-hoc analysis was performed to determine the relationship between the timing and magnitude of DAS28(ESR) response and long term outcomes in Japanese patients after 1 year of CZP treatment. Methods. Our analysis included 82 J-RAPID trial patients treated with CZP 200 mg and methotrexate, and 116 HIKARI trial patients treated with CZP 200 mg alone or with disease-modifying agents other than methotrexate. Remission rates and changes in mTSS at year 1 were compared to the DAS28(ESR) response at week 12 of CZP treatment. Results. After 1 year of treatment, remission was achieved in 41.3% of the J-RAPID and 34.9% of the HIKARI patients with a week 12 DAS28(ESR) response of ≥ 1.2. In comparison, patients with a DAS28(ESR) response of ≥ 1.2 at week 12 only had a ≥ 7% probability of achieving remission and displayed higher change in mTSS after 1-year treatment. Conclusions. The likelihood of remission and extent of radiographic progression after 1 year was associated with the week 12 DAS28(ESR) response. The DAS28(ESR) response at 12 weeks could be benefi cial for identifying patients that are unlikely to respond to prolonged CZP treatment.

Original languageEnglish
Pages (from-to)11-20
Number of pages10
JournalModern Rheumatology
Volume25
Issue number1
DOIs
Publication statusPublished - 2014 May 20

Fingerprint

Rheumatoid Arthritis
Methotrexate
Therapeutics
Certolizumab Pegol

Keywords

  • Certolizumab pegol
  • Long-term outcomes
  • Radiographic progression
  • Remission
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis : Results from the Japanese studies. / Takeuchi, Tsutomu; Yamamoto, Kazuhiko; Yamanaka, Hisashi; Ishiguro, Naoki; Tanaka, Yoshiya; Eguchi, Katsumi; Watanabe, Akira; Origasa, Hideki; Shoji, Toshiharu; Miyasaka, Nobuyuki; Koike, Takao.

In: Modern Rheumatology, Vol. 25, No. 1, 20.05.2014, p. 11-20.

Research output: Contribution to journalArticle

Takeuchi, T, Yamamoto, K, Yamanaka, H, Ishiguro, N, Tanaka, Y, Eguchi, K, Watanabe, A, Origasa, H, Shoji, T, Miyasaka, N & Koike, T 2014, 'Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: Results from the Japanese studies', Modern Rheumatology, vol. 25, no. 1, pp. 11-20. https://doi.org/10.3109/14397595.2014.904475
Takeuchi, Tsutomu ; Yamamoto, Kazuhiko ; Yamanaka, Hisashi ; Ishiguro, Naoki ; Tanaka, Yoshiya ; Eguchi, Katsumi ; Watanabe, Akira ; Origasa, Hideki ; Shoji, Toshiharu ; Miyasaka, Nobuyuki ; Koike, Takao. / Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis : Results from the Japanese studies. In: Modern Rheumatology. 2014 ; Vol. 25, No. 1. pp. 11-20.
@article{aa1d2aff9a85481e987fc78126859cd0,
title = "Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: Results from the Japanese studies",
abstract = "Objectives. A post-hoc analysis was performed to determine the relationship between the timing and magnitude of DAS28(ESR) response and long term outcomes in Japanese patients after 1 year of CZP treatment. Methods. Our analysis included 82 J-RAPID trial patients treated with CZP 200 mg and methotrexate, and 116 HIKARI trial patients treated with CZP 200 mg alone or with disease-modifying agents other than methotrexate. Remission rates and changes in mTSS at year 1 were compared to the DAS28(ESR) response at week 12 of CZP treatment. Results. After 1 year of treatment, remission was achieved in 41.3{\%} of the J-RAPID and 34.9{\%} of the HIKARI patients with a week 12 DAS28(ESR) response of ≥ 1.2. In comparison, patients with a DAS28(ESR) response of ≥ 1.2 at week 12 only had a ≥ 7{\%} probability of achieving remission and displayed higher change in mTSS after 1-year treatment. Conclusions. The likelihood of remission and extent of radiographic progression after 1 year was associated with the week 12 DAS28(ESR) response. The DAS28(ESR) response at 12 weeks could be benefi cial for identifying patients that are unlikely to respond to prolonged CZP treatment.",
keywords = "Certolizumab pegol, Long-term outcomes, Radiographic progression, Remission, Rheumatoid arthritis",
author = "Tsutomu Takeuchi and Kazuhiko Yamamoto and Hisashi Yamanaka and Naoki Ishiguro and Yoshiya Tanaka and Katsumi Eguchi and Akira Watanabe and Hideki Origasa and Toshiharu Shoji and Nobuyuki Miyasaka and Takao Koike",
year = "2014",
month = "5",
day = "20",
doi = "10.3109/14397595.2014.904475",
language = "English",
volume = "25",
pages = "11--20",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis

T2 - Results from the Japanese studies

AU - Takeuchi, Tsutomu

AU - Yamamoto, Kazuhiko

AU - Yamanaka, Hisashi

AU - Ishiguro, Naoki

AU - Tanaka, Yoshiya

AU - Eguchi, Katsumi

AU - Watanabe, Akira

AU - Origasa, Hideki

AU - Shoji, Toshiharu

AU - Miyasaka, Nobuyuki

AU - Koike, Takao

PY - 2014/5/20

Y1 - 2014/5/20

N2 - Objectives. A post-hoc analysis was performed to determine the relationship between the timing and magnitude of DAS28(ESR) response and long term outcomes in Japanese patients after 1 year of CZP treatment. Methods. Our analysis included 82 J-RAPID trial patients treated with CZP 200 mg and methotrexate, and 116 HIKARI trial patients treated with CZP 200 mg alone or with disease-modifying agents other than methotrexate. Remission rates and changes in mTSS at year 1 were compared to the DAS28(ESR) response at week 12 of CZP treatment. Results. After 1 year of treatment, remission was achieved in 41.3% of the J-RAPID and 34.9% of the HIKARI patients with a week 12 DAS28(ESR) response of ≥ 1.2. In comparison, patients with a DAS28(ESR) response of ≥ 1.2 at week 12 only had a ≥ 7% probability of achieving remission and displayed higher change in mTSS after 1-year treatment. Conclusions. The likelihood of remission and extent of radiographic progression after 1 year was associated with the week 12 DAS28(ESR) response. The DAS28(ESR) response at 12 weeks could be benefi cial for identifying patients that are unlikely to respond to prolonged CZP treatment.

AB - Objectives. A post-hoc analysis was performed to determine the relationship between the timing and magnitude of DAS28(ESR) response and long term outcomes in Japanese patients after 1 year of CZP treatment. Methods. Our analysis included 82 J-RAPID trial patients treated with CZP 200 mg and methotrexate, and 116 HIKARI trial patients treated with CZP 200 mg alone or with disease-modifying agents other than methotrexate. Remission rates and changes in mTSS at year 1 were compared to the DAS28(ESR) response at week 12 of CZP treatment. Results. After 1 year of treatment, remission was achieved in 41.3% of the J-RAPID and 34.9% of the HIKARI patients with a week 12 DAS28(ESR) response of ≥ 1.2. In comparison, patients with a DAS28(ESR) response of ≥ 1.2 at week 12 only had a ≥ 7% probability of achieving remission and displayed higher change in mTSS after 1-year treatment. Conclusions. The likelihood of remission and extent of radiographic progression after 1 year was associated with the week 12 DAS28(ESR) response. The DAS28(ESR) response at 12 weeks could be benefi cial for identifying patients that are unlikely to respond to prolonged CZP treatment.

KW - Certolizumab pegol

KW - Long-term outcomes

KW - Radiographic progression

KW - Remission

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84983437159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983437159&partnerID=8YFLogxK

U2 - 10.3109/14397595.2014.904475

DO - 10.3109/14397595.2014.904475

M3 - Article

C2 - 24842476

AN - SCOPUS:84983437159

VL - 25

SP - 11

EP - 20

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 1

ER -